Table 3.
Clinical characteristics of patients with critical COVID-19 disease, NI-SIRS, sepsis, and septic shock
| Critical COVID-19 n = 10 | NI-SIRS n = 7 | Sepsis n = 7 | Septic shock n = 14 | |
| Male, n (%) | 7 (70%) | 4 (57%) | 5 (71%) | 8 (57%) |
| Age (years) | 66 (52–75) | 54 (46–59) | 68 (56–75) | 60 (48–72) |
| Comorbidities | ||||
| Hypertension | 7 (70%) | 2 (29%) | 4 (57%) | 6 (43%) |
| Diabetes | 2 (20%) | 1 (14%) | 2 (29%) | 3 (21%) |
| Pneumopathy | 3 (30%) | 0 | 0 | 0 |
| Heart disease | 3 (30%) | 1 (14%) | 1 (14%) | 1 (7%) |
| Active malignancy | 0 | 0 | 0 | 0 |
| Other immunosuppression | 2 (20%) | 0 | 1 (14%) | 0 |
| Chronic kidney disease | 2 (20%) | 0 | 0 | 0 |
| Primary diagnoses | ||||
| Infection source | 0 | |||
| Urinary | 2 (29%) | 3 (22%) | ||
| Pulmonary | 3 (43%) | 5 (71%) | 3 (22%) | |
| Soft tissues | 1 (14%) | 0 | 3 (22%) | |
| Endovascular | 2 (29%) | 0 | 2 (14%) | |
| Central Nervous System | 1 (14%) | 0 | 2 (14%) | |
| Abdominal | 0 | 1 (7%) | ||
| Cardiac surgery | 0 | 0 | ||
| Pulmonary surgery | 0 | 0 | ||
| Cardiovascular disease | 0 | 0 | ||
| Pulmonary Thromboembolism | 0 | 0 | ||
| APACHE II score | 14 (8–16) | 10 (9–20) | 15 (12–25) | 21 (14–25)∗ |
| SOFA II score | 4 (3–6) | 6 (5–12) | 7 (6–8)† | 11 (9–14)† |
| CRP (mg/dL) | 14 (4–24) | 6 (2,5–13) | 23 (3–30) | 28 (22–34)∗ |
| Platelet count (109/L) | 244 (187–302) | 132 (115–214) | 255 (171–280) | 153 (65–196)∗ |
| ICU length of stay (days) | 14 (6–34) | 4 (2–7)∗ | 3 (2–7)† | 10 (4–16) |
| Hospital length of stay (days) | 20 (12–33) | 11 (7–14)∗ | 10 (8–17)∗ | 18 (13–54) |
| 28-day mortality | 1 (10%) | 0 | 0 | 5 (36%) |
| Invasive Mechanical ventilation | 3 (30%) | 5 (57%) | 1 (14%) | 6 (43%) |
| Renal replacement therapy | 3 (30%) | 1 (14%) | 1 (14%) | 3 (21%) |
Data are expressed as median (interquartile range) or absolute count (percentage).
∗
P < 0.05 compared with critical COVID-19 group.
†
P < 0.01 compared with critical COVID-19 group.
APACHE indicates Acute Physiology and Chronic Health Evaluation; CRP, C-reactive protein; ICU, intensive care unit; NI-SIRS, noninfectious systemic inflammatory response syndrome; SOFA, Sequential Organ Failure Assessment.